Evidence map›Paper›PMID 40974432›Full record

ReviewMedical oncology (Northwood, London, England)2025

Kinesin superfamily proteins in ovarian cancer: from molecular mechanisms to clinical applications.

Ashok Kumar Bishoyi, Shaker Al-Hasnaawei, Subbulakshmi Ganesan, Aman Shankhyan, Anima Nanda, Aashna Sinha, Subhashree Ray, Deepak Nathiya

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ashok Kumar BishoyiFaculty of Science, Department of Microbiology, Marwadi University Research Center, Marwadi University, Rajkot, Gujarat, India.
Shaker Al-HasnaaweiCollege of Pharmacy, The Islamic University, Najaf, Iraq.
Subbulakshmi GanesanDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
Aman ShankhyanCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, Punjab, 140401, India.
Anima NandaDepartment of Biomedical, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India. animananda.biomed@sathyabama.ac.in.
Aashna SinhaDivision of Research and Innovation, School of Applied and Life Sciences, Uttaranchal University, Dehradun, Uttarakhand, India.
Subhashree RayDepartment of Biochemistry IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India.
Deepak NathiyaDepartment of Pharmacy Practice, NIMS Institute of Pharmacy, NIMS University Rajasthan, Jaipur, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer remains one of the most lethal malignancies affecting women, largely due to its asymptomatic onset and frequent diagnosis at advanced stages. Emerging evidence has underscored the pivotal role of kinesin superfamily proteins (KIFs) in orchestrating the cellular mechanisms underlying tumor initiation and progression, particularly in ovarian cancer. These microtubule-associated motor proteins are essential for intracellular transport, cell division, signal transduction, and organelle positioning. Dysregulation of KIFs has been implicated in enhanced cellular proliferation, metastasis, and resistance to chemotherapy. In ovarian cancer, specific KIF members have been shown to promote cell motility and interfere with key signaling pathways, thereby accelerating tumor progression. Elevated expression levels of certain KIFs correlate with poor patient prognosis and reduced overall survival. This review consolidates current insights into the role of KIFs in ovarian cancer pathogenesis and emphasizes their potential as therapeutic targets. Elucidating the mechanistic involvement of KIFs in this malignancy may pave the way for innovative diagnostic, prognostic, and therapeutic strategies aimed at improving clinical outcomes in this highly aggressive cancer type.

Indexed as

KinesinsOvarian NeoplasmsAnimalsFemaleHumansPrognosisSignal TransductionKinesinsBiomarkerFemale cancerKIFsKinesin superfamilyOvarian cancer

Identifiers

PMID40974432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.